Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 8, 2010, Pages 3390-3394

  Zvada, Simbarashe P ^a   Van Der Walt, Jan Stefan ^a,b   Smith, Peter J ^a   Fourie, P Bernard ^c   Roscigno, Giorgio ^d   Mitchison, Denis ^e   Simonsson, Ulrika S H ^b   McIlleron, Helen M ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UPPSALA UNIVERSITY   (Sweden)

^c Medicine in Need South Africa   (South Africa)

^d FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

25 DEACETYLRIFAPENTINE; DRUG METABOLITE; RIFAPENTINE; WATER;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FOOD DRUG INTERACTION; HUMAN; LIPID DIET; LOW FAT DIET; MALE; MYCOBACTERIUM TUBERCULOSIS; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; ANTIBIOTICS, ANTITUBERCULAR; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DIETARY FATS; FASTING; HUMANS; MALE; RIFAMPIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955387983     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00345-10     Document Type: Article

References (38)

1. Beal, S. L., L. B. Sheiner, and A. Boeckmann. 1996. NONMEM users' guides. University of California, San Fransisco, San Francisco, CA.
2. Blumberg, H. M., W. J. Burman, R. E. Chaisson, C. L. Daley, S. C. Etkind, L. N. Friedman, P. Fujiwara, M. Grzemska, P. C. Hopewell, M. D. Iseman, R. M. Jasmer, V. Koppaka, R. I. Menzies, R. J. O'Brien, R. R. Reves, L. B. Reichman, P. M. Simone, J. R. Starke, and A. A. Vernon. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
3. Bock, N. N., T. R. Sterling, C. D. Hamilton, C. Pachucki, Y. C. Wang, D. S. Conwell, A. Mosher, M. Samuels, and A. Vernon. 2002. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am. J. Respir. Crit. Care Med. 165:1526-1530.
4. Burman, W., D. Benator, A. Vernon, A. Khan, B. Jones, C. Silva, C. Lahart, S. Weis, B. King, B. Mangura, M. Weiner, and W. El-Sadr. 2006. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am. J. Respir. Crit. Care Med. 173:350-356.
5. Burman, W. J., K. Gallicano, and C. Peloquin. 2001. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 40:327-341.
6. Chan, S. L., W. W. Yew, J. H. Porter, K. P. McAdam, B. W. Allen, J. M. Dickinson, G. A. Ellard, and D. A. Mitchison. 1994. Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. Int. J. Antimicrob. Agents 3:267-274.
7. Dooley, K., C. Flexner, J. Hackman, C. A. Peloquin, E. Nuermberger, R. E. Chaisson, and S. E. Dorman. 2008. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob. Agents Chemother. 52:4037-4042.
8. Gordi, T., R. Xie, N. V. Huong, D. X. Huong, M. O. Karlsson, and M. Ashton. 2005. A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Br. J. Clin. Pharmacol. 59:189-198.
9. Gumbo, T., A. Louie, M. R. Deziel, W. Liu, L. M. Parsons, M. Salfinger, and G. L. Drusano. 2007. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51:3781-3788.
10. Heifets, L. B., P. J. Lindholm-Levy, and M. A. Flory. 1990. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 141:626-630.
11. Holford, N. 2005. The visual predictive check-superiority to standard diagnostic (Rorschach) plots, abstr. 738. Abstr. 14th PAGE Meeting.
12. Holford, N. H., R. J. Ambros, and K. Stoeckel. 1992. Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil. J. Pharmacokinet. Biopharm. 20:421-442.
13. Jonsson, E. N., and M. O. Karlsson. 1999. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64.
14. Karlsson, M. O., and R. M. Savic. 2007. Diagnosing model diagnostics. Clin. Pharmacol. Ther. 82:17-20.
15. Karlsson, M. O., and L. B. Sheiner. 1993. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J. Pharmacokinet. Biopharm. 21:735-750.
16. Kerbusch, T., U. Wahlby, P. A. Milligan, and M. O. Karlsson. 2003. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br. J. Clin. Pharmacol. 56:639-652.
17. Keung, A., M. G. Eller, K. A. McKenzie, and S. J. Weir. 1999. Single and multiple dose pharmacokinetics of rifapentine in man: part II. Int. J. Tuberc. Lung Dis. 3:437-444.
18. Langdon, G., J. Wilkins, L. McFadyen, H. McIlleron, P. Smith, and U. S. Simonsson. 2005. Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients. Antimicrob. Agents Chemother. 49:4429-4436.
19. Langdon, G., J. J. Wilkins, P. J. Smith, and H. McIlleron. 2004. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 8:862-867.
20. Menzies, D., A. Benedetti, A. Paydar, I. Martin, S. Royce, M. Pai, A. Vernon, C. Lienhardt, and W. Burman. 2009. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med. 6:e1000146.
21. Mitchison, D. A. 1998. Development of rifapentine: the way ahead. Int. J. Tuberc. Lung Dis. 2:612-615.
22. Niemi, M., J. T. Backman, M. F. Fromm, P. J. Neuvonen, and K. T. Kivisto. 2003. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 42:819-850.
23. Relling, M. V., R. R. Evans, S. Groom, W. R. Crom, and C. B. Pratt. 1993. Saturable elimination and saturable protein binding account for flavone acetic acid pharmacokinetics. J. Pharmacokinet. Biopharm. 21:639-651.
24. Roberts, M. S., B. M. Magnusson, F. J. Burczynski, and M. Weiss. 2002. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin. Pharmacokinet. 41:751-790.
25. Rosenthal, I. M., K. Williams, S. Tyagi, C. A. Peloquin, A. A. Vernon, W. R. Bishai, J. H. Grosset, and E. L. Nuermberger. 2006. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am. J. Respir. Crit. Care Med. 174:94-101.
26. Rosenthal, I. M., M. Zhang, K. N. Williams, C. A. Peloquin, S. Tyagi, A. A. Vernon, W. R. Bishai, R. E. Chaisson, J. H. Grosset, and E. L. Nuermberger. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4:e344.
27. Rousseau, A., F. Leger, Y. Le Meur, F. Saint-Marcoux, G. Paintaud, M. Buchler, and P. Marquet. 2004. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Ther. Drug Monit. 26:23-30.
28. Savic, R. M., D. M. Jonker, T. Kerbusch, and M. O. Karlsson. 2007. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34:711-726.
29. Sirgel, F. A., P. B. Fourie, P. R. Donald, N. Padayatchi, R. Rustomjee, J. Levin, G. Roscigno, J. Norman, H. McIlleron, and D. A. Mitchison. 2005. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 172:128-135.
30. Taft, D. R., G. R. Iyer, L. Behar, and R. V. DiGregorio. 1997. Application of a first-pass effect model to characterize the pharmacokinetic disposition of venlafaxine after oral administration to human subjects. Drug Metab. Dispos. 25:1215-1218.
31. Wahlby, U., E. N. Jonsson, and M. O. Karlsson. 2001. Assessment of actual significance levels for covariate effects in NONMEM. J. Pharmacokinet. Pharmacodyn. 28:231-252.
32. Wehrli, W. 1983. Rifampin: mechanisms of action and resistance. Rev. Infect. Dis. 5(Suppl. 3):S407-S411.
33. Weiner, M., D. Benator, W. Burman, C. A. Peloquin, A. Khan, A. Vernon, B. Jones, C. Silva-Trigo, Z. Zhao, and T. Hodge. 2005. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin. Infect. Dis. 40: 1481-1491.
34. Weiner, M., N. Bock, C. A. Peloquin, W. J. Burman, A. Khan, A. Vernon, Z. Zhao, S. Weis, T. R. Sterling, K. Hayden, and S. Goldberg. 2004. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am. J. Respir. Crit. Care Med. 169:1191-1197.
35. Wilkins, J. J. 2005. NONMEMory: a run management tool for NONMEM. Comput. Methods Programs Biomed. 78:259-267.
36. Zai, H., M. Kusano, H. Hosaka, Y. Shimoyama, A. Nagoshi, M. Maeda, O. Kawamura, and M. Mori. 2009. Monosodium L-glutamate added to a high-energy, high-protein liquid diet promotes gastric emptying. Am. J. Clin. Nutr. 89:431-435.
37. Zhang, T., M. Zhang, I. M. Rosenthal, J. H. Grosset, and E. L. Nuermberger. 2009. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 180:1151-1157.
38. Zhu, M., S. Kaul, P. Nandy, D. M. Grasela, and M. Pfister. 2009. Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. Antimicrob. Agents Chemother. 53: 2346-2353.